What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Pesquisar
Categorias
Leia mais
Tendências
Germany Pharmaceutical CDMO Market Size, Share & Industry Forecast 2025–2035
The Germany Pharmaceutical CDMO Market is on a steady upward trajectory, valued at USD 8.04...
Por Rushikesh Nemishte 2026-07-27 06:07:39 0 0
Oportunidade
Access Mats Market Share and Competitive Landscape
Market Overview The Access Mats industry outlook reflects growing demand for temporary...
Por Vikas Hundekar 2026-06-13 10:20:24 0 0
Oportunidade
Satellite Ground Station Equipment Market Forecast 2025-2035: How LEO Constellation Expansion and Software-Defined Systems Are Driving Ground Segment Innovation
The global satellite ground station equipment market is experiencing significant growth, driven...
Por Atharva Parte 2026-08-17 10:17:35 0 0
Religião
The Rising Trend of Biodegradable Water Bottles in the Global Market
  As per Market Research Future, the Biodegradable Water Bottles Industry is poised for...
Por Suryakant Gadekar 2025-12-04 12:02:05 0 0
Conteúdo Técnico
API Security Market Report Demand Rising Across Global Enterprise Cloud Networks
The API Security Market Report Demand is increasing rapidly as enterprises worldwide...
Por Akanksha Bhoite 2026-05-07 07:18:37 0 0